Literature DB >> 17097835

Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer.

Dae Yong Kim1, Kyung Hae Jung, Tae Hyun Kim, Duck-Woo Kim, Hee Jin Chang, Jun Yong Jeong, Young Hoon Kim, Seok-Hyun Son, Tak Yun, Chang Won Hong, Dae Kyung Sohn, Seok-Byung Lim, Hyo Seong Choi, Seung-Yong Jeong, Jae-Gahb Park.   

Abstract

PURPOSE: To describe our experience with a bolus injection of 5-fluorouracil and leucovorin (FL) vs. capecitabine in terms of radiologic and pathologic findings in preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer.
METHODS: The study enrolled 278 patients scheduled for preoperative CRT using two protocols with different chemotherapeutic regimens. Pelvic radiotherapy (50.4 Gy) was delivered concurrently with FL (n = 145) or capecitabine (n = 133). Surgery was performed 6 weeks after CRT completion. Tumor responses to CRT were measured using both radiologic and pathologic examination. Magnetic resonance volumetry was performed at the initial workup and just before surgery after completion of preoperative CRT. Post-CRT pathology tests were used to determine tumor stage and regression.
RESULTS: Radiologic examination showed that tumor volume decreased by 68.2% +/- 20.5% in the FL group and 68.3% +/- 22.3% in the capecitabine group (p = 0.970). Postoperative pathologic T stage determination showed that downstaging occurred in 44.3% of FL and 49.9% of capecitabine patients (p = 0.571). The tumor regression grades after CRT were Grade 1 (minimal response) in 22.6% and 21.0%, Grade 2 (moderate response) in 53.2% and 50.0%, Grade 3 (near-complete response) in 12.9% and 12.9%, and Grade 4 (complete response) in 11.3% and 16.1% of the FL and capecitabine groups, respectively (p = 0.758).
CONCLUSION: In the present study, the radiologic and pathologic findings did not reveal significant differences in short-term tumor responses between preoperative FL and capecitabine CRT for locally advanced rectal cancer. Long-term results and a prospective randomized trial are needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097835     DOI: 10.1016/j.ijrobp.2006.08.063

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  32 in total

1.  Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.

Authors:  J Winkler; L Zipp; J Knoblich; F Zimmermann
Journal:  Strahlenther Onkol       Date:  2012-03-10       Impact factor: 3.621

Review 2.  Multidisciplinary management in rectal cancer.

Authors:  Asunción Hervás Morón; María Luisa García de Paredes; Eduardo Lobo Martínez
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

3.  Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer.

Authors:  Ting Jin; Yuan Zhu; Jia-Lin Luo; Ning Zhou; De-Chuan Li; Hai-Xin Ju; Yong-Tian Fan; Yong Liu; Yu-Ping Zhu; Hai-Yang Feng; Lu-Ying Liu
Journal:  Int J Colorectal Dis       Date:  2015-01-08       Impact factor: 2.571

4.  Capecitabine with radiation is an effective adjuvant therapy in gastric cancers.

Authors:  Chee Kian Tham; Su Pin Choo; Donald Yew Hee Poon; Han Chong Toh; Simon Yew Kuang Ong; Sze Huey Tan; Michael Lian Chek Wang; Kian Fong Foo
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

5.  Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy.

Authors:  Jong Wan Kim; Hyun Chul Kim; Ji Won Park; Sung Chan Park; Dae Kyung Sohn; Hyo Seong Choi; Dae Yong Kim; Hee Jin Chang; Ji Yeon Baek; Sun Young Kim; Seok Ki Kim; Jae Hwan Oh
Journal:  Int J Colorectal Dis       Date:  2013-02-13       Impact factor: 2.571

Review 6.  The role of capecitabine in locally advanced rectal cancer treatment: an update.

Authors:  Carlos Fernández-Martos; Miquel Nogué; Paloma Cejas; Víctor Moreno-García; Ana Hernández Machancoses; Jaime Feliu
Journal:  Drugs       Date:  2012-05-28       Impact factor: 9.546

7.  Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: Prognostic factors.

Authors:  Sofia Conde; Margarida Borrego; Tânia Teixeira; Rubina Teixeira; Anabela Sá; Paula Soares
Journal:  Rep Pract Oncol Radiother       Date:  2012-08-21

Review 8.  Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain.

Authors:  C Grávalos; P García-Alfonso; R Afonso; V Arrazubi; A Arrivi; J C Cámara; J Capdevila; A Gómez-España; A Lacasta; J L Manzano; M Salgado; J Sastre; E Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

9.  Patterns of failure in rectal cancer with positive circumferential resection margin after surgery following preoperative chemoradiation: a propensity score matching analysis.

Authors:  Youngkyong Kim; Dae Yong Kim; Tae Hyun Kim; Sun Young Kim; Ji Yeon Baek; Min Ju Kim; Hee Jin Chang; Yongjun Cha; Sung Chan Park; Jae Hwan Oh
Journal:  Br J Radiol       Date:  2018-09-12       Impact factor: 3.039

10.  Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.

Authors:  Vaneja Velenik; Irena Oblak; Franc Anderluh
Journal:  Radiat Oncol       Date:  2010-09-29       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.